Japan Tobacco Inc. · TSE:2914

Japan Tobacco — Technical Presentation (June 2018)

10 slides from Japan Tobacco's technical presentation, Jun 5, 2018

  1. Slide 1: Reduced-Risk Products Science Update

    Reduced-Risk Products Science Update Dr. Ian Jones, PhD JTI VP, Reduced-Risk Products Science Forward-Looking Statements This presentation contains forward-looking statements. These statements appear in a number of places in this document and include statements regarding the intent, belief, or curre

  2. Slide 2: Science is central to our RRP business

    This presentation contains images of our products in some slides. Those slides have been included exclusively to illustrate JT Group’s strategy or performance to our investors. They are not to be used for any other purpose. © Copyright JT 2018 London – June 5, 2018 JT Investor Conference 3 Science i

  3. Slide 3: Broadening spectrum of consumer needs

    Broadening spectrum of consumer needs Focus on Reduced-Risk potential Consumers are increasingly Social Convenience Consideration interested in experiences and products that address a broadening spectrum of $ personal and social needs Affordability Reduced Risk Potential Satisfaction © Copyright JT

  4. Slide 4: The JT Group approach to assessment of RRP

    The JT Group approach to assessment of RRP The emission is our starting point 1 EMISSION What comes out of the product 2 UPTAKE Users’ exposure to emissions & uptake into the body 3 EFFECT Biological effects of uptake into the body 4 INDOOR AIR QUALITY Environmental impact simulations © Copyright JT

  5. Slide 5: Emission: The risk cliff concept

    1) 1 Emission│ The risk cliff concept Potential risk-reduction in T-Vapor products Cigarettes ettes Temperature may be an indicator of risk HIGHER Charcoal Heated Heated Tobacco Tobacco Infused Vapor LOWER 800 700 600 500 400 300 200 100 0 o C © Copyright JT 2018 London – June 5, 2018 JT Investor Co

  6. Slide 6: Uptake: Clinical study design

    2) 2 Uptake│ Clinical study design Biomarkers of exposure Existing adult 60 adult smokers smokers 20 subjects randomly selected used Ploom TECH 20 subjects Screened Randomized smoking abstinent 20 subjects continued to smoke The subjects used products ad libitum for 5 days © Copyright JT 2018 London

  7. Slide 7: Effect: Less biological impact compared to smoking

    3) 3 Effect│ Less biological impact compared to smoking Analysis of cell viability Reference cigarette Commercially available Commerc Tobacco product Heated To [Cell Viability] 100% E-cigarette A E-cigarett 90% E-cigarette B E-cigarett TECH Ploom TE 80% 70% 60% 50% 40% 30% 20% 10% 0% Puffs/L (logari

  8. Slide 8: Observably less effect on tissue model, even at 10 times more puffs

    3) 3 Effect│ Observably less effect on tissue model, even at 10 times more puffs In vitro airway model Control 0 Puffs/L (before exposure) Smoking 200 Puffs/L (3R4F cigarette) 2,000 Puffs/L © Copyright JT 2018 London – June 5, 2018 JT Investor Conference 15 Reference: Internal JT Group Studies. 4) 4

  9. Slide 9: Indoor Air Quality: Minimal impact

    4) 4 Indoor Air Quality│ Minimal impact Simulation of an occupied smoking lounge [Units] Cigarette Use Ploom TECH Use No Product Use 1,000.0 100.0 10.0 1.0 0.1 Solanesol Nicotine 3-Ethenyl Formaldehyde Acetaldehyde Acetone Toluene TVOC PG Glycerol CO Ammonia SPM (ug/m3) (ug/m3) pyridine (ug/m3) (ug/

  10. Slide 10: Committed to scientific communication

    Committed to scientific communication Follow our progress at JT-Science.com © Copyright JT 2018 London – June 5, 2018 JT Investor Conference 19

Japan Tobacco — Technical Presentation (June 2018) on 6ix